Total Payments
$1.3M
2024 Payments
$104,534
Companies
42
Transactions
1,117
Medicare Patients
21,058
Medicare Billing
$2.1M
Payment Breakdown by Category
Research$813,117 (62.7%)
Other$265,608 (20.5%)
Consulting$150,704 (11.6%)
Travel$44,542 (3.4%)
Food & Beverage$22,274 (1.7%)
Education$179.98 (0.0%)
Gifts$8.03 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $813,117 | 220 | 62.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $257,213 | 84 | 19.8% |
| Consulting Fee | $150,704 | 49 | 11.6% |
| Travel and Lodging | $44,542 | 192 | 3.4% |
| Food and Beverage | $22,274 | 566 | 1.7% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $5,720 | 1 | 0.4% |
| Honoraria | $2,675 | 2 | 0.2% |
| Education | $179.98 | 2 | 0.0% |
| Gift | $8.03 | 1 | 0.0% |
Payments by Type
Research
$813,117
220 transactions
General
$483,315
897 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bausch Health US, LLC | $701,603 | 189 | $0 (2022) |
| Regeneron Healthcare Solutions, Inc. | $164,615 | 223 | $0 (2024) |
| PFIZER INC. | $91,138 | 113 | $0 (2024) |
| Valeant Pharmaceuticals North America LLC | $85,191 | 22 | $0 (2017) |
| GENZYME CORPORATION | $72,768 | 71 | $0 (2024) |
| Incyte Corporation | $53,546 | 67 | $0 (2024) |
| ABBVIE INC. | $27,741 | 151 | $0 (2024) |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $19,412 | 33 | $0 (2024) |
| Evolved By Nature, Inc. | $16,000 | 4 | $0 (2024) |
| LEO Pharma AS | $15,785 | 5 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $104,534 | 207 | Regeneron Healthcare Solutions, Inc. ($33,315) |
| 2023 | $110,332 | 199 | Regeneron Healthcare Solutions, Inc. ($43,538) |
| 2022 | $67,477 | 92 | Bausch Health US, LLC ($40,000) |
| 2021 | $84,710 | 91 | Bausch Health US, LLC ($48,045) |
| 2020 | $251,930 | 98 | Bausch Health US, LLC ($208,200) |
| 2019 | $386,358 | 202 | Bausch Health US, LLC ($288,410) |
| 2018 | $173,547 | 135 | Bausch Health US, LLC ($116,948) |
| 2017 | $117,544 | 93 | Valeant Pharmaceuticals North America LLC ($85,191) |
All Payment Transactions
1,117 individual payment records from CMS Open Payments — Page 1 of 45
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $94.87 | General |
| Category: IMMUNOLOGY | ||||||
| 12/23/2024 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $15.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $16.39 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $6.55 | General |
| Category: Dermatology | ||||||
| 12/18/2024 | Ortho Dermatologics, a division of Bausch Health US, LLC | SILIQ (Drug) | Food and Beverage | In-kind items and services | $19.79 | General |
| Category: Dermatology | ||||||
| 12/17/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $24.75 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/13/2024 | PFIZER INC. | CIBINQO (Drug), LITFULO | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: Inflammation & Immunology | ||||||
| 12/10/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/06/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $2,135.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/06/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $403.43 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/03/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPEVIGO (Drug) | Consulting Fee | Cash or cash equivalent | $2,325.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $15.99 | General |
| Category: IMMUNOLOGY | ||||||
| 11/29/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $8.41 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $177.72 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/26/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $177.71 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/26/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $45.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/26/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $13.07 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/26/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $11.99 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/25/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $8.69 | General |
| Category: Dermatology | ||||||
| 11/21/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $30.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/21/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.74 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/21/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $13.53 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/21/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $5.39 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/20/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY | Bausch Health US, LLC | $110,880 | 22 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | Bausch Health US, LLC | $98,000 | 25 |
| MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IDP-124 LOTION FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN PEDIATRIC AND ADULT SUBJECTS | Bausch Health US, LLC | $84,880 | 24 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS | Bausch Health US, LLC | $62,000 | 16 |
| A Multicenter, Open Label, Single-Arm Study evaluating the Safety and Pharmacokinetics of Efinaconazole 10 Topical Solution in Subjects with Mild to Severe Onychomycosis of the Toenails | Valeant Pharmaceuticals North America LLC | $59,680 | 8 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IDP-124 LOTION FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN PEDIATRIC AND ADULT SUBJECTS | Bausch Health US, LLC | $47,600 | 14 |
| A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Study to Evaluate the Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects | Bausch Health US, LLC | $46,039 | 15 |
| A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2 ARM, PARALLEL GROUP STUDY COMPARING THE SAFETY AND EFFICACY OF IDP-120 GEL AND IDP-120 VEHICLE GEL IN THE TREATMENT OF ACNE VULGARIS | Bausch Health US, LLC | $45,960 | 8 |
| A PHASE 4, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE ABSORPTION AND SYSTEMIC PHARMACOKINETICS AND HPA AXIS SUPPRESSION POTENTIAL OF TOPICALLY APPLIED IDP-118 LOTION IN PEDIATRIC SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | Bausch Health US, LLC | $37,800 | 11 |
| A PHASE 4, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE ABSORPTION AND SYSTEMIC PHARMACOKINETICS AND HPA AXIS SUPPRESSION POTENTIAL OF TOPICALLY APPLIED IDP-122 LOTION IN PEDIATRIC SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | Bausch Health US, LLC | $35,550 | 10 |
| A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP STUDY COMPARING THE SAFETY AND EFFICACY OF IDP-120 GEL AND IDP-120 VEHICLE IN THE TREATMENT OF ACNE VULAGRIS | Bausch Health US, LLC | $33,640 | 8 |
| A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2 ARM, PARALLEL GROUP STUDY COMPARING THE SAFETY AND EFFICACY OF IDP-123 LOTION AND IDP-123 VEHICLE LOTION IN THE TREATMENT OF ACNE VULGARIS | Bausch Health US, LLC | $33,600 | 9 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | Valeant Pharmaceuticals North America LLC | $21,674 | 6 |
| A MULTICENTER, OPEN LABEL, SINGLE-ARM STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF EFINACONAZOLE 10 TOPICAL SOLUTION IN SUBJECTS WITH MILD TO SEVERE ONYCHOMYCOSIS OF THE TOENAILS | Bausch Health US, LLC | $19,468 | 2 |
| A PHASE 1B OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE SAFETY AND SYSTEMIC PHARMACOKINETICS OF TOPICALLY APPLIED IDP-124 LOTION IN PEDIATRIC SUBJECTS WITH ATOPIC DERMATITI | Bausch Health US, LLC | $14,400 | 4 |
| DELGOCITINIB CREAM FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS DURING 8 WEEKS IN ADULTS, ADOLESCENTS, AND CHILDREN | LEO Pharma AS | $14,285 | 4 |
| CRISABOROLE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $9,940 | 8 |
| A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris | Bausch Health US, LLC | $9,841 | 4 |
| A PHASE 1B OPEN-LABEL STUDY EVALUATING THE ABSORPTION AND SYSTEMIC PHARMACOKINETICS OF TOPICALLY APPLIED IDP-126 GEL IN COMPARISON WITH EPIDUO FORTE GEL IN SUBJECTS WITH MODERATE TO SEVERE ACNE VULGARIS UNDER MAXIMAL USE CONDITIONS | Bausch Health US, LLC | $4,000 | 3 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | Bausch Health US, LLC | $4,000 | 1 |
| A Phase 1b Open-Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics of Topically Applied IDP-126 Gel in Comparison with EpiDuo Forte Gel 0.3 adapalene2.5 BPO in Subjects with Acne Vulgaris under Maximal Use Conditions | Bausch Health US, LLC | $4,000 | 1 |
| A PHASE 1B, OPEN-LABEL RANDOMIZED STUDY EVALUATING THE SAFETY AND SYSTEMIC PHARMACOKINETICS OF TOPICALLY APPLIED IDP?124 LOTION IN PEDIATRIC SUBJECTS WITH ATOPIC DERMATITIS | Bausch Health US, LLC | $3,600 | 1 |
| A PHASE 4 (PHASE 2 IN EUROPEAN UNION), OPEN-LABEL, MULTICENTER STUDY EVALUATING THE ABSORPTION AND SYSTEMIC PHARMACOKINETICS AND HPA AXIS SUPPRESSION POTENTIAL OF TOPICALLY APPLIED IDP-118 LOTION IN PEDIATRIC SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | Bausch Health US, LLC | $3,150 | 6 |
| LAMELLAR ICHTHYOSIS PHASE II | MAYNE PHARMA INC. | $2,700 | 1 |
| A PHASE 4 (PHASE 2 IN EUROPEAN UNION), OPEN-LABEL, MULTICENTER STUDY EVALUATING THE ABSORPTION AND SYSTEMIC PHARMACOKINETICS AND HPA AXIS SUPPRESSION POTENTIAL OF TOPICALLY APPLIED IDP-122 LOTION IN PEDIATRIC SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | Bausch Health US, LLC | $2,250 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY IN PATIENTS 12 TO 18 YEARS OF AGE, WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $1,780 | 4 |
| A TRIAL EVALUATING THE SAFETY AND EFFICACY OF ONCE DAILY TOPICAL TREATMENT WITH LEO 90100 AEROSOL FOAM IN ADOLESCENT SUBJECTS WITH PLAQUE PSORIASIS | LEO Pharma AS | $1,500 | 1 |
| AN OPEN-LABEL, SINGLE-DOSE STUDY TO EVALUATE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF BRODALUMAB IN PEDIATRIC SUBJECTS 6 TO 18 YEARS OLD WITH SEVERE PLAQUE PSORIASIS | Bausch Health US, LLC | $900.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 4,222 | 13,043 | $1.3M | $438,119 |
| 2022 | 28 | 6,478 | 16,247 | $1.8M | $626,510 |
| 2021 | 27 | 5,936 | 15,948 | $1.7M | $628,523 |
| 2020 | 24 | 4,422 | 12,435 | $1.3M | $439,976 |
Total Patients
21,058
Total Services
57,673
Medicare Billing
$2.1M
Procedure Codes
100
All Medicare Procedures & Services
100 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 3,020 | 10,252 | $976,900 | $324,561 | 33.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 218 | 309 | $49,440 | $18,479 | 37.4% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 63 | 100 | $27,000 | $13,611 | 50.4% |
| 96910 | Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | Office | 2023 | 12 | 113 | $17,515 | $11,619 | 66.3% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 112 | 136 | $29,920 | $9,985 | 33.4% |
| 96900 | Application of ultraviolet light to skin | Office | 2023 | 32 | 399 | $21,945 | $8,426 | 38.4% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2023 | 19 | 27 | $18,900 | $8,148 | 43.1% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 165 | 203 | $26,390 | $8,029 | 30.4% |
| 88304 | Pathology examination of tissue using a microscope, moderately low complexity | Office | 2023 | 127 | 250 | $13,190 | $4,947 | 37.5% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 125 | 824 | $14,008 | $4,504 | 32.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 39 | 42 | $9,450 | $3,833 | 40.6% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 47 | 49 | $11,515 | $3,801 | 33.0% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 11 | 13 | $8,385 | $2,971 | 35.4% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Office | 2023 | 25 | 63 | $6,767 | $2,729 | 40.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 39 | 39 | $8,775 | $2,616 | 29.8% |
| 96567 | Application of light to destroy precancer skin growth | Office | 2023 | 19 | 23 | $6,900 | $2,596 | 37.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 58 | 62 | $5,704 | $2,320 | 40.7% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 29 | 39 | $4,680 | $1,674 | 35.8% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 12 | 13 | $6,825 | $1,527 | 22.4% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 26 | 26 | $4,030 | $1,106 | 27.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 24 | 61 | $3,050 | $637.47 | 20.9% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2022 | 2,808 | 9,596 | $910,430 | $300,250 | 33.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 667 | 759 | $117,505 | $45,933 | 39.1% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 263 | 342 | $92,340 | $44,566 | 48.3% |
| 96910 | Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | Office | 2022 | 18 | 357 | $55,335 | $37,819 | 68.3% |
About Jeffrey Sugarman, M.D., PH.D
Jeffrey Sugarman, M.D., PH.D is a Pediatric Dermatology healthcare provider based in Santa Rosa, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/16/2005. The National Provider Identifier (NPI) number assigned to this provider is 1548255482.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Jeffrey Sugarman, M.D., PH.D has received a total of $1.3M in payments from pharmaceutical and medical device companies, with $104,534 received in 2024. These payments were reported across 1,117 transactions from 42 companies. The most common payment nature is "" ($813,117).
As a Medicare-enrolled provider, Sugarman has provided services to 21,058 Medicare beneficiaries, totaling 57,673 services with total Medicare billing of $2.1M. Data is available for 4 years (2020–2023), covering 100 distinct procedure/service records.
Ad
Practice Information
- Specialty Pediatric Dermatology
- Other Specialties Dermatology, Procedural Dermatology
- Location Santa Rosa, CA
- Active Since 09/16/2005
- Last Updated 03/28/2017
- Taxonomy Code 207NP0225X
- Entity Type Individual
- NPI Number 1548255482
Products in Payments
- DUPIXENT (Biological) $191,340
- JUBLIA (Drug) $79,148
- EUCRISA (Drug) $50,826
- OPZELURA (Drug) $45,224
- DUOBRII (Drug) $42,300
- CIBINQO (Drug) $37,784
- DUPIXENT DUPILUMAB INJECTION (Biological) $27,271
- DUPIXENT (Drug) $24,318
- RINVOQ (Biological) $19,352
- ALTRENO (Drug) $6,863
- Humira (Biological) $6,344
- COSENTYX (Biological) $5,132
- Zoryve (Drug) $2,439
- SPEVIGO (Drug) $2,374
- SKYRIZI (Biological) $1,703
- SILIQ (Drug) $1,119
- VTAMA (Drug) $1,096
- TALTZ (Drug) $597.99
- Levulan (Drug) $521.36
- Sotyktu (Drug) $402.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.